MPD-75
| Clinical data | |
|---|---|
| Other names | MPD75; 1-Methyl-N-pyrrolidyllysergamide; 1-Methyllysergic acid pyrrolidide; 1-Methyl-LA-pyrrolidineamide; (1,6-Dimethyl-9,10-didehydroergolin-8β-yl)(pyrrolidin-1-yl)methanone |
| Routes of administration | Oral |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H25N3O |
| Molar mass | 335.451 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MPD-75, also known as 1-methyl-N-pyrrolidyllysergamide or as 1-methyllysergic acid pyrrolidide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the 1-methyl derivative of lysergic acid pyrrolidide (LA-Pyr; LPD-824) and the N-pyrrolidide analogue of 1-methyl-LSD (MLD-41).
The drug was evaluated in humans and was found to produce partial LSD-like effects. It was reported to have had a faster onset and shorter duration compared to LSD. MPD-75 showed less than 5% of the potency of LSD in producing LSD-like effects, with a required dose of >20 μg/kg or >1.6 mg orally. According to another source however, MPD-75 had 7% of the potency of LSD in humans. For comparison, LA-Pyr had approximately 10% of the potency of LSD and had more full LSD-like effects, while 1-methyl-LSD had 33% of the potency of LSD and likewise produced full LSD-like effects.
In animal studies, MPD-75 had 4% of the toxicity of LSD in rabbits (presumably in terms of LD50), 0% of its pyretogenic activity in rabbits, and 130% of its antiserotonergic activity in the isolated rat uterus.
MPD-75 was first described in the scientific literature by Albert Hofmann and colleagues by 1957. It has not been encountered as a designer drug as of 2020.